About The Position

The Senior Advisor – Metabolic Health will provide clinical and research expertise on metabolic health, GLP‑1 therapies, and health economics. This role involves advising on clinical design, access criteria, and the interpretation of evidence and health economic implications related to GLP‑1 therapies. The advisor will also stay informed on the latest clinical, market, and research trends, and contribute to the development of various policy and research documents.

Requirements

  • M.D. with specialization in Cardiology
  • Completion of graduate level education (Master’s or higher) in Health Economics, Health Services Research, Pharmacoeconomics, Health Policy, or related fields
  • 15+ years of relevant professional experience
  • Publication record in peer‑reviewed journals on GLP‑1s
  • Engagement with professional societies (e.g., AHA, ACC, SGIM)
  • Demonstrated expertise in cardiometabolic disease and GLP‑1 pharmacotherapy
  • Ability to evaluate population‑level utilization and access impacts
  • Active license as a practicing cardiologist

Responsibilities

  • Participate in meetings with SCMG‑DDI staff.
  • Advise on clinical design features and access criteria for GLP‑1s.
  • Provide expertise on most recent clinical, market, and research trends.
  • Provide SME feedback on ICIPs, RFAs, policy documents, and model materials.
  • Offer expert interpretation of GLP‑1 evidence and health economic implications.
  • Advise on methodological credibility and interpretation of findings.
  • Inform staff on emerging GLP‑1 literature, cardiometabolic research, and clinical best practices.
  • Advise on epidemiologic and economic considerations affecting utilization and access.
  • SME guidance on clinical access criteria and value‑based prioritization for GLP‑1 therapies.
  • Presentations summarizing latest GLP‑1 evidence (clinical outcomes, utilization trends).
  • Expert review of policy documents, external communications, and guidance materials.
  • Support development of briefing papers related to GLP‑1 utilization, payment, and trends.
  • Engagement in dissemination efforts to clinical and research communities.
© 2026 Teal Labs, Inc
Privacy PolicyTerms of Service